Login to Your Account



Amgen drug gets FDA nod as first biosimilar to treat cancer

By Mari Serebrov
Regulatory Editor

Thursday, September 14, 2017

The FDA triggered another biosimilar first Thursday with its right-on-schedule approval of Amgen Inc.'s Mvasi.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription